Timothy Coughlin net worth and biography

Timothy Coughlin Biography and Net Worth

Director of aTyr Pharma

Timothy P. Coughlin has served as a director since April 2017, and as Chairman of our Board of Directors since March 2024. Mr. Coughlin is the former Chief Financial Officer of Neurocrine Biosciences, Inc. (Neurocrine), a biopharmaceutical company that has received U.S. Food and Drug Administration approval for INGREZZA® and ORILISSA®, both of which were discovered, developed and commercialized during his tenure at Neurocrine from 2002 to 2018. Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors from 1989 to 1999. Mr. Coughlin serves on the board of directors of Travere Therapeutics, Inc. and ADC Therapeutics SA, both biotechnology companies. He also served on the board of directors of Peloton Therapeutics prior to its sale to Merck & Co in 2019 and Fate Therapeutics, Inc. from 2013 to 2025. Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.

What is Timothy Coughlin's net worth?: The estimated net worth of Timothy Coughlin is at least $693.75 thousand as of October 31st, 2025. Mr. Coughlin owns 55,500 shares of aTyr Pharma stock worth more than $693,750 as of March 13th. This net worth estimate does not reflect any other investments that Mr. Coughlin may own. Learn More about Timothy Coughlin's net worth.
How do I contact Timothy Coughlin?: The corporate mailing address for Mr. Coughlin and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Timothy Coughlin's contact information.
Has Timothy Coughlin been buying or selling shares of aTyr Pharma?: Timothy Coughlin has not been actively trading shares of aTyr Pharma in the last ninety days. Most recently, on Thursday, May 30th, Timothy Coughlin bought 50,000 shares of aTyr Pharma stock. The stock was acquired at an average cost of $1.75 per share, with a total value of $87,500.00. Following the completion of the transaction, the director now directly owns 56,000 shares of the company's stock, valued at $98,000. Learn More on Timothy Coughlin's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Timothy Coughlin (Director), Brandt Kucharski (CAO), Erin Lantz (CRO), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last twelve months, aTyr Pharma insiders bought shares 3 times. They purchased a total of 526,313 shares worth more than $9,999,947.00. In the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 2,020,413 shares worth more than $38,188,227.30. The most recent insider tranaction occured on January, 30th when Director William J Wheeler bought 260,525 shares worth more than $4,949,975.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 1/30/2026.

Timothy Coughlin Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/30/2024	Buy	50,000	$1.75	$87,500.00	56,000

Timothy Coughlin Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Today's Range

Now: $12.50

$12.16

$12.83

50 Day Range

MA: $1.76

$1.57

$2.07

2 Week Range

Now: $12.50

$1.08

$2.45

Volume

657,503 shs

Average Volume

514,103 shs

Market Capitalization

$862.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19